Skip to main content
SpringerLink
Log in

Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp. and Haemophilus influenzae

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

Disk diffusion susceptibility interpretive criteria for tebipenem against Staphylococcus spp. and Haemophilus influenzae were developed using the Clinical and Laboratory Standards Institute (CLSI) guidelines. Tebipenem was tested by disk diffusion and broth microdilution methods against 119 clinical isolates of Staphylococcus spp. and 102 clinical isolates of H. influenzae. The zone diameters of 5-, 10-, and 30-μg disks were compared with broth microdilution minimum inhibitory concentration (MIC) results by scattergram and regression analysis. When the MIC breakpoint of 1 μg/ml was applied to the scattergrams, the 10-μg disk showed good correlation between the zone diameters and the MIC values. The corresponding disk diffusion zone diameter breakpoints with the 10-μg disk for Staphylococcus spp. were ≧22 mm (MIC ≦1 μg/ml) for susceptible, 20–21 mm (MIC = 2 μg/ml) for intermediate, and ≦19 mm (MIC ≧4 μg/ml) for resistant. We also proposed the breakpoint zone diameter of H. influenzae: ≧22 mm (MIC ≦1 μg/ml) for susceptible. These criteria demonstrated that the categorical agreements between disk diffusion and broth microdilution methods for Staphylococcus spp. and H. influenzae were 95.0% and 99.0%, respectively. The discrepancy rates of these criteria were acceptable to the CLSI guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem® fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–94.

    CAS  Google Scholar 

  2. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement, M100-S19. Wayne, PA: CLSI; 2009.

  3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard, tenth edition, M02-A10. Wayne, PA: CLSI; 2009.

  4. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, eighth edition, M07-A8. Wayne, PA: CLSI; 2009.

  5. Clinical and Laboratory Standards Institute. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline, third edition, M23-A3. Wayne, PA: CLSI; 2008.

  6. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline, second edition, M23-A2. Wayne, PA: CLSI; 2001.

  7. Report from the Committee on Antimicrobial Susceptibility Testing. Japanese Society of Chemotherapy (1989). Chemotherapy (Tokyo). 1990;38:102–5.

    Google Scholar 

  8. Report from the Committee on Antimicrobial Susceptibility Testing. Japanese Society of Chemotherapy (1992). Chemotherapy (Tokyo). 1993;41:183–9.

    Google Scholar 

  9. Report of the Committee for Japanese Standards for Antimicrobial Susceptibility Testing for Bacteria. Clinical breakpoint for antimicrobial agents in pulmonary infections and sepsis. Chemotherapy (Tokyo). 1994;42:905–14.

  10. Baba S, Kasahara H, Morita J, Aizawa K, Sunakawa K. Tissue and aural discharge distribution of tebipenem pivoxil. Jpn J Antibiot. 2009;62:127–35.

    CAS  PubMed  Google Scholar 

  11. Totsuka K, Aizawa K, Morita J, Hori S, Sunakawa K. PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91.

    Google Scholar 

  12. Ubukata K, Chiba N, Morozumi M, Hamano-Hasegawa K. Antibiotic susceptibility and resistance gene analysis of Streptococcus pneumoniae in clinical tebipenem-pivoxil studies in pediatric patients using PCR method. Jpn J Chemother. 2009;57(S-1):58–66.

    CAS  Google Scholar 

  13. Kishii K, Chiba N, Morozumi M, Hamano-Hasegawa K, Kimiko U. Antibiotic susceptibility and resistance gene analysis of Haemophilus influenzae in clinical tebipenem-pivoxil studies in pediatric patients using PCR method. Jpn J Chemother. 2009;57(S-1):67–75.

    CAS  Google Scholar 

  14. Yamada K, Sugano T, Baba N, Takayama Y, Mikuniya T, Maebashi K. In vitro antimicrobial activity of tebipenem. Jpn J Chemother. 2009;57(S-1):1–14.

    CAS  Google Scholar 

  15. Fuchs P, Barry A, Brown S. Selection of zone size interpretive criteria for disk diffusion susceptibility tests of three antibiotics against Streptococcus pneumoniae, using the new guidelines of the National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother. 2002;46:398–401.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Meiji Seika Kaisha, Ltd. for their cooperation and for providing the clinical isolates.

Author information

Authors and Affiliations

  1. Biochemical Research Laboratories, R&D Division, Eiken Chemical Co., Ltd., 143 Nogi, Nogi-machi Shimotsuga-gun, Tochigi, 329-0014, Japan

    Momoko Fujisaki, Shinya Sadamoto & Masanari Ikedo

  2. Department of Infectious Diseases, Tokyo Women’s Medical University, Tokyo, Japan

    Kyoichi Totsuka

  3. Department of Infection Control and Laboratory Diagnostics Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

    Mitsuo Kaku

  4. Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan

    Kazuhiro Tateda & Keizo Yamaguchi

  5. Department of Clinical Microbiology with Epidemiological Research and Management and Analysis of Infectious Diseases, Tohoku University Graduate School of Medicine, Sendai, Japan

    Yoichi Hirakata

Authors
  1. Momoko Fujisaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinya Sadamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masanari Ikedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyoichi Totsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuo Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Tateda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoichi Hirakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keizo Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Momoko Fujisaki.

About this article

Cite this article

Fujisaki, M., Sadamoto, S., Ikedo, M. et al. Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp. and Haemophilus influenzae . J Infect Chemother 17, 17–23 (2011). https://doi.org/10.1007/s10156-010-0091-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-010-0091-3

Keywords

Search

Navigation